4.6 Article

Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis

Journal

WORLD JOURNAL OF GASTROENTEROLOGY
Volume 20, Issue 41, Pages 15163-15176

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v20.i41.15163

Keywords

Intestinal microbiota; Bifidobacterium; Probiotics; Dysbiosis; Inflammatory bowel disease; Irritable bowel syndrome; Colorectal cancer; Liver disease; Respiratory disease; Functional foods

Funding

  1. Spanish Ministry of Economy and Competitiveness
  2. FEDER European Union [AGL2010-14952, AGL2010-16525, AGL2012-33278]

Ask authors/readers for more resources

The pool of microbes inhabiting our body is known as microbiota and their collective genomes as microbiome. The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition (dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases (inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract (e.g., allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobac-terium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available